From: Hsa-miR-375 is a predictor of local control in early stage breast cancer
Clinical outcome | Â | Â | Â | Â | Â |
---|---|---|---|---|---|
Parameters | Pilot phase n = 32 | Validation phase n = 115 | |||
Relapse n = 16 | Control n = 16 | Relapse n = 30 | Control n = 85 | ||
Time to local relapse (months) | Median | 37 | x | 74 | x |
Range | 15–123 | x | 35–185 | x | |
Time to distant metastasis (months) | Median | 61 | x | 70 | 49.5 |
Range | 20–96 | x | 27–118 | 9–109 | |
Follow-up (months) | Median | 121.5 | 130.5 | 125 | 140 |
Range | 26–192 | 72–200 | 44–214 | 17–207 | |
Lost to follow-up (n) | 0 | 0 | 0 | 1 (1.2Â %) | |
Cancer specific deaths (n) | Â | 4 (25Â %) | 0 | 7 (23.3Â %) | 2 (2.4Â %) |